Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Biogen Strengthens Pipeline With Stoke Therapeutic’s Dravet Syndrome Candidate Via Multi-Million Dollar Deal
